Heart failure

Gout drugs may also help fight heart failure – Consumer Health News

MONDAY, May 23, 2022 (HealthDay News) — The anti-inflammatory benefits of a common gout drug could help save the lives of heart failure patients, researchers say.

Medication, colchicinemay also reduce the risk of heart attack and stroke in patients whose arteries are clogged with cholesterol, according to the study authors.

“The signal of benefit from colchicine in these patients was very impressive, and I expect these results to have quite a significant impact on clinical care in heart failure and future research for patients with this condition. disease,” Dr. Kenneth Bilchick said at a university. of Virginia (UVA) press release. He is a professor of cardiovascular medicine there.

For the study, Bilchick and his team analyzed the records of more than 1,000 patients admitted to the university’s medical center between March 2011 and February 2020 for worsening heart failure, which occurs when the heart cannot pump enough blood through the body.

Survival rates were almost 98% for those who received colchicine for a gout attack, compared to less than 94% for those who did not receive colchicine.

Many heart failure patients also have dropa type of arthritis caused by a buildup of uric acid crystals in the joints.

Common treatments for gout include colchicine, steroids, and nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen. However, steroids and NSAIDs are generally not given to patients with heart failure, as they may worsen heart failure symptoms.

Colchicine may benefit patients with heart failure by reducing inflammation in the heart and blood vessels, the researchers suggested.

Although these early results need to be confirmed in large studies, the research team said they are promising.

“These findings highlight the importance of novel inflammatory mechanisms in heart failure,” Bilchick said.

Heart failure is more than just a failure in the pumping function of the heart, said Dr. Sula Mazimba, a researcher and cardiologist at the UVA School of Medicine. “Other processes are involved, especially during an acute hospitalization phase, such as elevated inflammation and neuro-hormonal process. Many therapeutic agents for heart failure target neuro-hormonal pathways, but few, if any, target inflammatory pathways,” Mazimba said. said.

“Colchicine is a drug that has anti-inflammatory properties that could potentially alleviate the increased inflammation that we see in patients hospitalized with heart failure,” Mazimba added.

About 6 million Americans suffer from heart failure and it causes more than 86,000 deaths a year, according to the American Heart Association.

The results of the study were published online recently in the journal Clinical cardiology.

More information

Learn more about heart failure at American Heart Association.

SOURCE: University of Virginia, press release, May 19, 2022

From articles on your site

Related articles on the web